Robert Hazlett
Stock Analyst at BTIG
(0.23)
# 3,827
Out of 4,829 analysts
23
Total ratings
33.33%
Success rate
-44.82%
Average return
Main Sectors:
Stocks Rated by Robert Hazlett
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AURA Aura Biosciences | Maintains: Buy | $21 → $24 | $5.35 | +349.02% | 3 | Oct 18, 2024 | |
| NKTR Nektar Therapeutics | Assumes: Buy | $4 | $0.71 | +459.60% | 2 | Sep 30, 2024 | |
| RANI Rani Therapeutics Holdings | Maintains: Buy | $7 → $14 | $0.61 | +2,183.85% | 2 | May 9, 2024 | |
| LYRA Lyra Therapeutics | Maintains: Buy | $24 → $20 | $0.09 | +21,131.42% | 1 | Feb 7, 2023 | |
| AXSM Axsome Therapeutics | Maintains: Buy | $62 → $98 | $110.16 | -11.04% | 2 | Dec 23, 2022 | |
| VSTM Verastem | Maintains: Buy | $96 → $60 | $7.29 | +723.05% | 3 | Oct 5, 2022 | |
| CMPS COMPASS Pathways | Initiates: Buy | $63 | $3.91 | +1,511.25% | 1 | May 27, 2021 | |
| PRTA Prothena Corporation | Upgrades: Buy | $29 | $7.61 | +281.08% | 4 | Feb 2, 2021 | |
| RDHL RedHill Biopharma | Initiates: Buy | $26,000 | $2.00 | +1,299,900.00% | 1 | Sep 11, 2020 | |
| AKBA Akebia Therapeutics | Maintains: Buy | $26 → $6 | $2.43 | +146.91% | 2 | Sep 4, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $12.18 | +47.78% | 2 | Aug 31, 2017 |
Aura Biosciences
Oct 18, 2024
Maintains: Buy
Price Target: $21 → $24
Current: $5.35
Upside: +349.02%
Nektar Therapeutics
Sep 30, 2024
Assumes: Buy
Price Target: $4
Current: $0.71
Upside: +459.60%
Rani Therapeutics Holdings
May 9, 2024
Maintains: Buy
Price Target: $7 → $14
Current: $0.61
Upside: +2,183.85%
Lyra Therapeutics
Feb 7, 2023
Maintains: Buy
Price Target: $24 → $20
Current: $0.09
Upside: +21,131.42%
Axsome Therapeutics
Dec 23, 2022
Maintains: Buy
Price Target: $62 → $98
Current: $110.16
Upside: -11.04%
Verastem
Oct 5, 2022
Maintains: Buy
Price Target: $96 → $60
Current: $7.29
Upside: +723.05%
COMPASS Pathways
May 27, 2021
Initiates: Buy
Price Target: $63
Current: $3.91
Upside: +1,511.25%
Prothena Corporation
Feb 2, 2021
Upgrades: Buy
Price Target: $29
Current: $7.61
Upside: +281.08%
RedHill Biopharma
Sep 11, 2020
Initiates: Buy
Price Target: $26,000
Current: $2.00
Upside: +1,299,900.00%
Akebia Therapeutics
Sep 4, 2020
Maintains: Buy
Price Target: $26 → $6
Current: $2.43
Upside: +146.91%
Aug 31, 2017
Initiates: Buy
Price Target: $18
Current: $12.18
Upside: +47.78%